Company profile: Airna
1.1 - Company Overview
Company description
- Provider of RNA editing technologies and therapeutics, including the RESTORE+ RNA editing platform to optimize sequence, chemistry, and delivery for precise RNA editing to treat rare and common diseases. Offers RNA editing therapeutics for alpha-1 antitrypsin deficiency (AATD) and a pipeline addressing diseases with high unmet need.
Products and services
- RESTORE+™ RNA editing platform: A precision-engineered technology system that optimizes therapeutic sequence, chemistry, and delivery to achieve precise RNA editing for rare and common diseases
- Pipeline of RNA editing therapeutics: A modular pipeline of therapeutic candidates developed using the RESTORE+™ platform to address diseases with high unmet need through optimized therapeutic sequence, chemistry, and delivery
- RNA editing therapeutics for alpha-1 antitrypsin deficiency (AATD): A custom-engineered therapeutic program targeting alpha-1 antitrypsin deficiency using AIRNA’s RNA editing technology to address this genetic disease
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Airna
Fluent Biosciences
HQ: United States
Website
- Description: Provider of single-cell molecular analysis solutions without complex microfluidic instrumentation via its PIPseq Pre-Templated Instant Partitions platform for instantaneous self-assembly. Offers 3’ Single Cell RNA Kits (T2, T20, T100) for profiling up to 100,000 cells, a nuclei isolation kit, unique dual index kits for Illumina NGS instruments, and supplemental enrichment/amplification kits.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fluent Biosciences company profile →
Centogene
HQ: Germany
Website
- Description: Provider of methods and technology for human genetics analysis, delivering genetic diagnostic analyses of rare inherited diseases and transforming global genetic data into medical decisions to create broader awareness for patients of all ethnicities around the world.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Centogene company profile →
Cobra Biologics
HQ: United Kingdom
Website
- Description: Provider of contract manufacturing for biologics and pharmaceuticals for pre-clinical, clinical, and commercial supply. An international CMO with three GMP-approved facilities in Sweden and the UK, offering expertise tailored to customers worldwide.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cobra Biologics company profile →
Immuneering
HQ: United States
Website
- Description: Provider of bioinformatics-driven drug discovery developing investigational medicines, including IMM-1-104 targeting RAS-mutant advanced solid tumors with once-daily oral dosing, and IMM-6-415, a Deep Cyclic Inhibitor for RAF or RAS-mutant advanced solid tumors with twice-daily dosing; also maintains an Expanded Access Policy (not currently available).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immuneering company profile →
GeneThera
HQ: United States
Website
- Description: Provider of biotechnology applying molecular technologies to improve food safety and eradicate zoonotic diseases, including Johne's Disease, Mad Cow Disease, Chronic Wasting Disease, and E.coli, affecting terrestrial, avian, and aquatic animals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GeneThera company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Airna
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Airna
2.2 - Growth funds investing in similar companies to Airna
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Airna
4.2 - Public trading comparable groups for Airna
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →